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In addition to its primary role as growth factor, human growth hormone (hGH) can also participate in cell survival, as already
documented by its protective effect on human monocytes or human promyelocytic leukaemia U937 cells exposed to a Fas-mediated
cell death signal. However, despite similarities in the molecular events following Fas and TNF-a receptor engagement, we report that
U937 cells, genetically engineered to constitutively produce hGH, were made more sensitive to TNF-a-induced apoptosis than
parental cells. This was due to overproduction of the antioxidant glutathione, which decreased the nuclear factor (NF)-kB activity
known to control the expression of survival genes. These findings were confirmed in vivo, in nude mice bearing U937 tumours
coinjected with recombinant hGH and the NF-kB -inducing anticancer drug daunorubicin, to avoid the in vivo toxicity of TNF-a. This
study therefore highlights one of the various properties of hGH that may have potential clinical implications.
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It has now been clearly established that the human growth
hormone (hGH), secreted by the pituitary gland, exerts various
important properties in addition to its fundamental role as a
growth factor (reviewed in van Buul-Offers and Kooijman, 1998).
This finding led to the use of hGH as adjuvant therapy in various
diseases, such as AIDS (Lee, 1996), heart failure (Sacca and Fazio,
1996) or Crohn’s disease (Slonim et al, 2000). Other recent studies
have also established the effect of hGH on cell survival, as hGH
may protect cells against various cell death inducers, such as
irradiation (Mylonas et al, 2000) or growth factor deprivation, via
nuclear factor (NF-kB)-kB activation (Jeay et al, 2000, 2001).
Nuclear factor-B/Rel transcription factors have emerged as key
factors in the regulation of inflammatory and immune responses
as well as cell survival (Pahl, 1999). For instance, the injection of
antisense to the p65 subunit of NF-kB inhibited the growth of
murine fibrosarcoma in vivo (Higgins et al, 1993) or murine and
human squamous cell carcinomas, in vitro (Duffey et al, 1999; van
Hogerlinden et al, 1999). Recently, Davis et al, (2001) comparing
gene expression profiling genes in diffuse large B-cell lymphoma
cells and in normal B cells from germinal centre clearly showed an
overexpression of NF-kB-targeted genes in tumour cells only,
which may participate in their survival cells (Davis et al, 2001).
Alternatively, inhibition of NF-kB activation may result in an
enhanced response to anticancer drug-induced tumour cell death.
This has been clearly evidenced in various cancer cells by transient
transfection of NF-kB subunits (Liu et al, 1996) or stable
transfection of gene encoding super-repressor form of IkB, the
natural inhibitor of NF-kB (Baeuerle and Baltimore, 1988). In these
situations, chemosensitivity was restored, as exemplified in drug-
exposed human pancreatic carcinoma cells in vitro (Arlt et al,
2001), in murine fibrosarcoma in vitro (Van Antwerp et al, 1996;
Wang et al, 1996) and in vivo (Wang et al, 1999a), or more recently
in human colorectal cancer cells in vivo (Cusack et al, 2000). All
these effects may be controlled via the NF-kB-mediated transcrip-
tion of survival genes, some of which have already been described,
such as the inhibitor-of-apoptosis (IAP) (Wang et al, 1998) or
immediate-early response gene IEX-1L (Wu et al, 1998), or
suppression of proapoptotic cytochrome c release from mitochon-
dria via activation of A1/Bfl-1, a member of the Bcl-2 family (Wang
et al, 1999b). More recently, it has been proposed that NF-kB may
blunt the c-Jun amino-terminal kinase (JNK)-dependent cell death
pathway by the transcription of JNK signalling inhibitors (De
Smaele et al, 2001; Tang et al, 2001). The NF-kB pathway may,
therefore, be a suitable target for anticancer therapy.
In a recent study, we also reported that hGH may modulate the
response of cells to apoptotic signals, demonstrating its beneficial
effect on the survival of human monocytes and promyelocytic
leukaemia U937 cells exposed to a proapoptotic signal mediated
via Fas engagement (Haeffner et al, 1999). In parallel, we exposed
our U937 cell lines to TNF-a, expecting similar protection, as Fas is
a member of the tumour necvosis factor (TNF) receptor super-
family (Itoh et al, 1991; Oehm et al, 1992), and shares common
signalling pathways with the type 1 TNF receptor (Hsu et al, 1996),
including in U937 cells (Schu ¨tze et al, 1992; Cifone et al, 1993). In
contrast, as reported herein, we observed that hGH sensitised U937
cells to the apoptotic signal induced by TNF-a. The effect of hGH is
mediated via a glutathione-dependent decrease in NF-kB translo-
cation normally observed in response to TNF-a. We also Received 21 October 2002; revised 6 June 2003; accepted 11 June 2003
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sconfirmed these findings in vivo, as injections of exogenous
recombinant hGH in U937 tumour-engrafted nude mice led to
increased tumour cell death together with decreased translocation
of NF-kB in cell nuclei, in response to subtoxic doses of
daunorubicin, an anthracycline agent activating NF-kB in our
cells (Cherbonnier et al, 2002).
MATERIALS AND METHODS
Cells and culture conditions
Two different human myeloid leukaemia U937 cell lines producing
10–50ngml
 1 of hGH after stable gene transfer (U937-hGH-A and
U937-hGH-H5) and the control line (U937-Neo), already described
(Haeffner et al, 1999), were maintained in regular FCS-enriched
RPMI 1640 medium (Bio-Whittaker Europe, Verviers, Belgium)
containing 0.5mgml
 1 of G418 (Life Technology, Paisley, Scot-
land).
Assessment of apoptosis
U937 cells (5 10
5) (the two hGH-transfected and the control
lines) in 0.5ml of culture medium were cultured for 48h in the
presence or absence of TNF-a (Innotest, Besanc¸on, France) with or
without 400ngml
 1 of cycloheximide (CHX, Sigma, St Louis, MO,
USA), as previously reported (Cossarizza et al, 1995). Dead cells
were detected either by trypan blue exclusion for experiments run
in the presence of recombinant hGH (rhGH, Saizen
s, kindly
provided by Serono France) at doses already experimented
(Haeffner et al, 1999) or by flow cytometry analysis of cell lines
after a 15min staining with propidium iodide (PI) (5mgml
 1 pi,
Sigma, St-Louis, MO, USA), using a FACScan (Becton Dickinson,
Mountain View, CA, USA). Hypoploid cell assessment was
measured on ethanol-permeabilised U937 cells exposed or not to
10ngml
 1 of TNF-a cultured overnight with or without
400ngml
 1 of cycloheximide (CHX), by staining with PI, as
previously described (Mollereau et al, 1996). In separate experi-
ments, we added glutathione ethyl ester (GSH-OEt) (Sigma) to the
culture of control U937 cells in the presence or absence of TNF-a.
NF-jB measurement
Cell lines were cultured for 90min in the presence of 10ngml
 1
TNF-a, and nuclear extracts were analysed by electrophoretic
mobility-shift assay (EMSA). Specificity was assessed by incubat-
ing nuclear extracts obtained from TNF-a-stimulated cells with
nonradiolabelled NF-kB probe (50-ACAAGGGACTTTCCGCTGGG-
GACTTTCCAG-30) or mutated NF-B (50-ACAACTCACTTTCC-
GCTGCTCACTTTCCAG-30) oligonucleotide probe, as previously
reported (Thieblemont et al, 1995). For supershift assays, anti-P50
and anti-P65 Abs (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were used, as reported in U937 cells (Giri et al, 1998). In
separate experiments, we analysed nuclear extracts from U937 cell
lines cultured in the absence or in the presence of TNF-a
(10ngml
 1, 90min)7rhGH. In other separate experiments, we
analysed nuclear extracts from U937 cell lines cultured in the
absence or in the presence of: TNF-a (10ngml
 1, 90min)7CHX
(400ngml
 1, 90min), or anti-Fas mAb (CH-11 anti-Fas mAb,
Immunotech, Marseille, France) (1mgml
 1, 90min). In both cases,
specificity was assessed by using the probes described above.
Alternatively, prior to nuclear extractions, U937 cells were
incubated with 10ngml
 1 of TNF-a alone or in addition to
various doses of glutathione ethyl-ester (GSH-OEt, Sigma).
IjB measurement
Cell lysates obtained from 5 10
5 cells with or without exposure to
5ngml
 1 of TNF-a were separated on 10% SDS–polyacrylamide
gel and electroblotted onto nitrocellulose membranes. In separate
experiments, U937 cells were incubated with 5ngml
 1 of TNF-a
alone or in addition to 20mM of GSH and U937-hGH cells were
incubated with 5ngml
 1 TNF-a alone or in addition to 50mM of
diethyl maleate (DEM) (Sigma), in conditions already used in our
models (De ´as et al, 1997). The same amounts of proteins based on
Bradford measurement were loaded onto the gel. Blots were first
stained with rabbit anti-IkBa (Santa-Cruz Biotechnology) or anti-
IkB Abs (kindly provided by A Israe ¨l, Institut Pasteur) after
striping, and then with anti-rabbit peroxidase-labelled second Abs
(Amersham). They were developed using an enhanced chemilu-
minescence detection system (ECL, Amersham, UK).
Glutathione measurement
The total glutathione level was measured by the glutathione
reductase recycling method, as previously described (De ´as et al,
1997). Glutathione is expressed in nmolmg
 1 of total protein
measured in cell extracts by the Bradford method.
In vivo experiments
U937 cells (10
7) were first injected subcutaneously into irradiated
6- to 8-week-old male nu/nu Swiss mice in order to obtain solid
tumours. Another group of mice was then engrafted with
fragments from these tumours (4mm
3), pooled and randomly
assigned to four groups of 10 mice: animals injected with saline
solution; animals injected with 1.5mgkg
 1 of daunorubicin
(dosage determined as previously reported (Cherbonnier et al,
2002); animals injected with 5mgkg
 1 of recombinant exogenous
hGH (rhGH) based on the study of the in vivo effects of rhGH in a
murine model of sepsis induced by Escherichia coli (Inoue et al,
1995); and animals injected with 1.5mgkg
 1 of daunorubicin and
5mgkg
 1 of rhGH. Daunorubicin was administered as a single
intraperitoneal injection on three consecutive days. Recombinant
exogenous rhGH was administered subcutaneously as a single
injection on four consecutive days, starting 2 days prior to the first
injection of daunorubicin. Animal body weights were recorded and
tumours were measured with calipers by the same investigator and
the volume was calculated according to the following equation: V
(mm
3)¼d
2 (mm
2) D (mm)/2, where d and D are the smallest
and perpendicular diameters, respectively. For ethical reasons, the
maximum tumour volume accepted was 2000mm
3. In a separate
experiment, mice were treated as described above and were killed
at various times. Fixed tumours were analysed by epifluorescence
for in situ apoptosis with terminal-deoxynucleotidyl-transferase-
mediated dUTP nick-end labelling (TUNEL) (Roche) or for in situ
NF-kB activation with rabbit anti-P65 Abs revealed with fluor-
escein-labelled goat anti-rabbit Abs, and nuclei were stained with
DAPI. Animals were killed under CO2 anaesthesia. All experiments
were carried out under the conditions established by the European
Union (Directive 86/609/EEC).
Statistical analysis
Statistical analyses were performed using Student’s t-test for in vitro
experiments. In vivo experiments were assessed using a nonpara-
metric Kruskal–Wallis test for tumour volume measurement, using
logrank test for Kaplan–Meier curves and a w
2 test for the
quantification of apoptosis and NF-kB activation on tissue sections.
RESULTS
Human growth hormone increases the sensitivity to
TNF-a-induced apoptosis
Based on our previous studies demonstrating that stable expres-
sion of hGH in cell lines could mimic the effect of exogenous GH
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s(Haeffner et al, 1999), we exposed our two hGH-producing human
myeloid leukaemia U937 cell lines and the control one to TNF-a
during 2-day cultures. As illustrated in Figure 1A, the percentage
of dead cells (PIþ) was higher for U937-hGH cells than for control
U937-Neo cells, in response to TNF-a (37.579.6% of PIþU937-
hGH cells treated with 10ngml
 1 of TNF-a, vs 16.775.6% of
PIþcells among TNF-a-treated control cell lines, mean7s.e.m.,
P¼0.001, n¼6). In contrast, hGH had no additional effect on
apoptosis of cells exposed to TNF-a in the presence of the protein
synthesis inhibitor CHX, known to potentiate TNF-a-induced
U937 cell death (Cossarizza et al, 1995). The difference between
hGH-producing cells and their controls was also demonstrated in
terms of apoptotic nuclear events, as evidenced by flow cytometry
of permeabilised cells allowing DNA content analysis (Figure 1B).
Under these conditions, after 20-h cultures, presence of hGH led
also to an increase in hypodiploid DNA in TNF-a-treated cells.
Finally, we confirmed that exogenous rhGH added to the cultures
of unmanipulated U937 cells rendered them more sensitive to
TNF-a-treatment (Figure 1C). Indeed, in these conditions, we
observed a statistically significant increased cell death in hGH-
treated U937 cells stimulated with 50ngml
 1 of TNF-a,a s
compared to U937 cells cultured in the absence of rhGH
(44.670.7% of dead U937 cells treated with 50ngml
 1 of TNF-a
in the presence of 5ngml
 1 of rhGH and 51.575.5% of dead U937
cells treated with 50ngml
 1 of TNF-a in the presence of
500ngml
 1 of rhGH, vs 35.270.6% among cells treated with
TNF-a- in the absence of rhGH, mean7s.e.m., Po0.05 and
Po0.01, respectively, n¼4).
Specific depressed NF-jactivation in cells treated with
TNF-a by hGH
As inhibition of NF-kB activation was clearly linked to increased
apoptosis of various tumour cells, we decided to test NF-kB DNA
binding activity in nuclear extracts from our cell lines incubated
with TNF-a, a potent NF-kB stimulator (Baeuerle and Baltimore,
1988). As illustrated in Figure 2A, the increase in NF-kB-DNA
binding activity observed in U937-Neo cells exposed to TNF-a
(lane 2), as compared to nonexposed cells (lane 1), was no longer
observed in U937-hGH cells treated under similar conditions
(lanes 4 and 3, respectively). Specificity was assessed by incubating
nuclear extracts obtained from TNF-a-treated control cells with
nonradiolabelled consensus NF-kB (lane 5) or mutated NFkB (lane
6) probe. Interactions of these nuclear extracts were also observed
with anti-P65 (lane 7) and, to a lesser extent, anti-P50 (lane 8) Abs,
confirming the detection of NF-kB.
To confirm the effect of hGH on NF-kB activity, in separate
experiment, parental U937 cells were coincubated with TNF-a and
various concentrations of rhGH. As shown in Figure 2B, TNF-a-
mediated NF-kB-DNA binding activity (lane 4) was decreased by
addition of 50ngml
 1 (lane 6) or 500ngml
 1 (lane 7) of rhGH.
NF-kB can interact with Fas-mediated apoptosis in various
situations (Zong et al, 1998; Dudley et al, 1999; Trauzold et al,
2001; Zheng et al, 2001), which prompted us to investigate the
effect of hGH on NF-kB translocation using nuclear extracts from
cells exposed to anti-Fas mAb (Figure 2C). No protein–DNA
complex was seen using extracts from U937-Neo and U937-hGH
cells exposed to anti-Fas mAb (lanes 4 and 8, respectively). As
expected, protein–DNA complexes were observed using nuclear
extracts from U937-Neo cells exposed to TNF-a (lane 2), and also
to TNF-a7CHX (lane 3), compared to unstimulated cells (lane 1).
These protein–DNA complexes were specifically competed by a
consensus NF-kB probe but not by the mutated probe (lanes 9 and
10, respectively). The present experiment also confirmed that NF-
kB translocation was strongly inhibited by hGH in response to a
TNF-a stimulus (lane 6), and was markedly diminished in response
to a TNF-aþCHX stimulus (lane 7).
Inhibition of TNF-a induced IjB degradation by hGH
Intracellular localisation of NF-kB can be closely monitored by its
interaction with members of the IkB family. In response to various
stimuli, IkB undergoes proteolytic degradation, which allows
nuclear translocation of NF-kB leading to gene activation
(Baeuerle and Baltimore, 1988 #733). To determine whether the
decreased activation of NF-kB observed in hGH-treated cells was
due to a modulation of Ik degradation, we performed Western blot
analyses on whole-cell extracts from our cell lines. After TNF-a
exposure, degradation of kB was observed in U937-Neo cells, while
no degradation was detected in U937-hGH cells, even after
incubation for 2h (Figure 3). Interestingly, IkBa (Figure 3) and
IkBb (not shown) were degraded to a similar degree in U937-Neo
control and in hGH-producing U937-Neo-cells exposed to TNF-a.
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Figure 1 Effect of hGH on TNF-a-induced apoptosis. U937-Neo and
U937-hGH cell lines were cultured in the presence or absence of TNF-a
(10ngml
 1) with or without CHX (400ngml
 1)( A) The percentage of
dead cells was measured by PI staining. The values represent the
mean7s.e.m. of six independent experiments (*P¼0.001). (B) The
percentage of cells with hypodiploid DNA content was detected by PI
staining of ethanol-permeabilised cells. Linear scales are represented. (C)
U937 cells were cultured for 48h in the presence or absence of 50ngml
 1
TNF-a with or without exogenous recombinant hGH at 5 or 500ngml
 1.
The percentage of dead cells was measured by trypan blue exclusion. The
values represent the mean7s.e.m. of four experiments (*Po0.05,
**Po0.01).
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sEffects of hGH-induced enhanced GSH production
The activation of NF-kB in response to various agents requires the
production of reactive oxidative intermediates (ROIs) (Janssen-
Heininger et al, 2000). Since glutathione, the most significant
intracellular thiol, is a potent ROI scavenger (Meister and
Anderson, 1983) with the potential to prevent NF-kB activation
(Janssen-Heininger et al, 2000), we first measured its production in
our cells. As illustrated in Figure 4A, U937-hGH cell lines produced
more total intracellular GSH than control cells. We therefore
decided to test whether direct addition of exogenous GSH to U937
control cells could mimic hGH treatment in vitro. Addition of
glutathione ethyl ester (GSH-OEt), a GSH analogue which can
enter cells due to its hydrophobic ester groups, increased cell death
in TNF-a-treated U937 cells (Figure 4B). These results were
statistically significant at 10mM GSH-OEt for the highest TNF-a
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NF- B
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B
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U937-Neo
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Figure 2 Effect of hGH on NF-kB activation. (A) An EMSA was
performed on nuclear extracts as described in Materials and Methods.
Control U937 or hGH-transfected cells were either nonstimulated (lanes 1
and 3, respectively) or stimulated with TNF-a (10ngml
 1) (lanes 2 and 4,
respectively). Nuclear factor-kB migration was assessed by migration of
nuclear extracts from U937-Neo cells stimulated with TNF-a, coincubated
with nonlabelled NF-kB-specific (lane 5) or NF-kB-mutated probes (lane
6), or with anti-P65 (lane 7) and anti-P50 (lane 8) NF-kB subunit
antibodies. (B) In a separate experiment, an EMSA was performed on
nuclear extracts from U937-Neo cells cultured in the absence or in the
presence of TNF-a (10ngml
 1) (lanes 3 and 4, respectively), coincubated
with 5, 50, or 500ngml
 1 of rhGH (lanes 5, 6 and 7, respectively). U937-
hGH cells were also stimulated with TNF-a (10ngml
 1) (lane 8). Nuclear
factor-kB migration was assessed by migration of nuclear extracts from
U937-Neo cells stimulated with TNF-a, and coincubated with nonlabelled
NF-kB-specific (lane 2) or NF-kB-mutated (lane 1) probes. (C) In another
experiment, U937-Neo and U937-hGH cells were either nonstimulated
(lanes 1 and 5, respectively), stimulated with TNF-a (10ngml
 1) (lanes 2
and 6, respectively), stimulated with TNF-a and CHX (400ngml
 1) (lanes
3 and 7, respectively) or stimulated with anti-Fas mAbs (lanes 4 and 8,
respectively). Specificity was assessed by migration of nuclear extracts from
U937-Neo cells stimulated with TNF-a, and coincubated with the probes
described above, nonlabelled NF-kB-specific (lane 9) or NF-kB-mutated
(lane 10) probes.
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Figure 3 Effect of hGH on IkB degradation. Whole-cell extracts from
the indicated cell lines stimulated with TNF-a (10ngml
 1) for 0–120min
were subjected to Western blotting using anti-IkB Abs under the
conditions described in Materials and Methods.
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Figure 4 (A) Effect of hGH on GSH production. The glutathione level
was measured in U937-Neo and U937-hGH cells under the conditions
described in Materials and Methods. The values represent the mean7
s.e.m. of four independent experiments (*Po0.05). (B) Effect of GSH-OEt
on TNF-a-induced apoptosis. U937-Neo cells were stimulated with TNF-a
in the presence or absence of GSH-OEt and under the conditions
described in Materials and Methods: the percentage of dead cells was
measured by PI staining. The values represent the mean7s.e.m. of three
independent experiments (*Po0.04, **Po0.03, ***Po0.02), when
comparing GSH-OEt treated cells to GSH-OEt non-treated cells in each
group. (C) Effect of GSH-OEt on NF-kB activation. Nuclear extracts were
analysed by EMSA for measurement of NF-kB activation, as described in
Figure 2. (D) Effect of GSH on IkB degradation. Whole-cell extracts were
subjected to Western blotting using anti-IkB Abs, as described in Figure 3.
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sconcentration used in this study, and at 20mM GSH-OEt for both
TNF-a concentrations. We then studied the effect of GSH-OEt on
both NF-kB activation and IkB degradation. The presence of GSH-
OEt depressed NF-kB-DNA binding activity in a dose-dependent
manner in U937-Neo cells treated with 10ngml
 1 of TNF-a
(Figure 4C). The presence of GSH-OEt (Figure 4D, lower left) in the
culture prevented the degradation of IkB that normally occurred
upon TNF-a-treatment only (Figure 4D, upper left). Moreover,
addition of DEM, a potent thiol-depleting agent, in cell cultures led
to IkB degradation in TNF-a-treated hGH-producing cells
(Figure 4D, lower right), while, as expected, a pattern of stabilised
IkB was shown in U937-hGH cells with an unmodified thiol level
(Figure 4D, upper right). Altogether, these results suggest that hGH
may control the response to TNF-a by modifying the redox status
of the cells.
In vivo sensitisation of tumours by rhGH
To extend and validate this study in vivo, we decided to use the
anticancer drug daunorubicin, as TNF-a, one of the main
cytokines involved in sepsis (reviewed in Dinarello, 2000), may
induce devastating effects after in vivo injection. Moreover,
daunorubicin, widely used in clinical practice, is able to induce
apoptosis and activate NF-kB in our cells (Cherbonnier et al,
2002). We therefore decided to study the effect of exogenous
recombinant hGH on chemotherapy delivered to nude mice
engrafted with parental unmodified U937 tumours. In order to
verify the proposed mechanism explaining the effect of hGH, in
vivo, we first examined in situ apoptosis in the various groups of
mice defined in Materials and Methods. A TUNEL assay reported
in Figure 5A clearly showed a greater number of fluorescent nuclei,
reflecting increased cell death in tumour cells of mice treated with
both daunorubicin and rhGH compared to daunorubicin-treated
mice (Po0.001), while no fluorescent nuclei were observed in the
two other groups. In addition, the limited nuclear staining revealed
with an anti-P65 NF-kB subunit Ab, evidenced a marked decrease
in NF-kB activation in tumour cells of mice treated with both
daunorubicin and rhGH, compared to the daunorubicin-treated
group (Po0.0001) (Figure 5B). Both effects were observed 2 days
after the last injection of daunorubicin (day 6). Similar analyses
performed on days 9 and 12 showed equivalent number of dead
cells and lack of NF-kB in cell nuclei, in both daunorubicin-treated
groups.
In parallel, the growth rate of U937 tumours was measured in
these mice. As shown in Figure 5C, this rate was reduced in mice
treated with the highest subtoxic dose of daunorubicin
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Figure 5 In vivo effect of hGH on daunorubicin treatment of engrafted
tumours. Small tumour fragments obtained from U937-Neo tumours were
transplanted subcutaneously in previously irradiated nude Swiss mice.
Tumour-bearing mice either received i.p. injections of saline solution or
subcutaneous injections of rhGH alone, or the highest subtoxic dose of
daunorubicin (1.5mgkg
 1) with or without 5mgkg
 1 of rhGH. (A) Tissue
sections from mice treated as above were submitted to TUNEL assay.
Note the significant number of stained nuclei in tumours from rhGH- and
daunorubicin-treated animals, indicating a high apoptosis rate in these
animals. (B) The same tumours were assessed for NF-kB activation, as
evidenced by the presence of the P65 subunit in the nuclei. Note the lower
number of stained nuclei in tumours from mice treated with rhGH and
daunorubicin, compared with daunorubicin-treated animals. (C) Tumour
volumes were measured in each group of mice. The measurement was
stopped when a mouse died or was killed because of a tumour volume
exceeding 2000mm
3. Each line represents the mean7s.e.m. of the tumour
volumes (*Po0.05 and **Po0.01, when comparing daunorubicin-treated
mice to mice receiving daunorubicin and rhGH). (D) Kaplan-Meier curve
comparing the different groups of mice with a tumour volume below
300mm
3. PBS-injected mice (y.), daunomycine-injected mice (.-.-.-.-.)
hGH-injected mice (- - -) and daunomycineþhGH-injected mice (—).
c
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s(1.5mgkg
 1, as defined in Materials and Methods) combined
with injections of 5mgkg
 1 of rhGH, while tumours remained
unaffected by treatment with daunorubicin only. Tumour
volumes were significantly different from the 6th day after
initiation of treatment until the 12th day, when comparing animals
treated with rhGH and daunorubicin to animals treated with
daunorubicin only (at day 6: 171714mm
3 vs 327753mm
3, n¼10,
*Po0.05 and at day 12: 320752mm
3 vs 7817159mm
3, n¼10,
*Po0.05). No further comparisons were possible due to death of
animals in the daunorubicin-treated group at day 12. No protective
effects were observed in mice receiving saline (Ctrl) or rhGH
only. Given the high growth rate of U937 cells in vivo and the
design of the present experiments in which only a single cure
was given to the mice, the complete eradication of tumours could
not be achieved. However, the survival of mice with a tumour
below 300mm
3 was determined. As shown in Figure 5D, the
survival of mice treated with both daunorubicine and rhGH
was significantly higher than in the different control groups
(Po0.008).
It should be noted that coadministration of rhGH and
daunorubicin did not induce any toxicity or body weight loss
(data not shown).
DISCUSSION
In a previous study, we demonstrated the ability of hGH to protect
human monocytes or U937 cells from cell death induced by Fas
engagement (Haeffner et al, 1999). Interestingly, despite molecular
similarities between Fas and TNF-a receptors (Itoh et al, 1991) and
common pathways in response to their engagement in various cell
lines, including U937 cells (Schu ¨tze et al, 1992; Cifone et al, 1993),
we report herein that hGH may potentiate TNF-a-induced U937
cell apoptosis (Figure 1). It has been clearly established that the cell
death signal mediated via engagement of TNF-a receptor can be
regulated by NF-kB activation subunits (Liu et al, 1996); (Van
Antwerp et al, 1996; Wang et al, 1996). In our study, we found that
NF-kB activation was markedly decreased in U937-hGH cells
exposed to TNF-a compared to treated U937-Neo cells (Figure 2A)
and in parental cells incubated with exogenous rhGH (Figure 2B).
These results therefore confirm our previous findings (Haeffner
et al, 1997) concerning the ability of hGH to modulate the NF-kB-
dependent pathway in response to various inducers. Fas cross-
linking may induce death or survival signalling, depending on the
cell type (Budd, 2002). Survival is linked to the engagement of
FLICE inhibitory protein (FLIP) that may phosphorylate IkB,
thereby activating NF-kB. As anti-Fas mAbs were unable to induce
NF-kB activation in our cells (Figure 2C), hGH may trigger another
pathway promoting cell survival in response to Fas. This difference
in NF-kB profile could therefore partly explain the opposite effects
observed with Fas and TNF-a.
As also reported in Figure 1, addition of protein synthesis
inhibitor CHX, in control cells cultured with TNF-a, induced an
expected increase in cell apoptosis (Cossarizza et al, 1995). Under
similar conditions, hGH, although still synthesised, as assessed by
ELISA (data not shown) was unable to improve cell death.
Moreover, the presence of CHX did not modify the NF-kB profile
in either U937-hGH or U937-Neo cells exposed to TNF-a
(Figure 2C). We can therefore speculate that hGH and CHX both
increase apoptosis by affecting the synthesis of survival proteins:
hGH acts upstream to NF-kB activation, while CHX acts down-
stream to NF-kB activation.
Activation of NF-kB, that is, its translocation in the cell nucleus,
occurs after proteosomal degradation of members of the IkB
family following phosphorylation by IkB kinases (IKK) (Mercurio
and Manning, 1999). One of these kinases, IKKb is essential for the
prevention of TNF-a-induced apoptosis (Senftleben et al, 2001).
The IkB family is composed of several a, b and e proteins
constitutively expressed and present in the cytosol, all sharing the
capacity to prevent NF-kB translocation, and the newly described z
protein localised in the nucleus (Yamazaki et al, 2001). Unexpect-
edly, we report that hGH regulated TNF-a-dependent NF-kB
activation via stabilisation of IkBe, and not IkBa, the main member
of the IkB family (Figure 3), or IkBb (data not shown). Although
unusual, this type of situation has already been described by other
authors in cells from IkB a-deficient mice in response to TNF-a
(Whiteside et al, 1997), or in other models (Doerre and Corley,
1999; Spiecker et al, 2000). Fischer et al (1999) also reported that
TNF-a may activate NF-kB via degradation of IkBe in human
monocytic THP1 cells. TNF-a-inducing NF-kB activation may
therefore involve various members of the IkB family, probably
depending on the cell type.
Tumour necrosis factor-a induces the release of ROIs (Goossens
et al, 1995) that are also considered to be potent NF-kB activators
in many cell types, including tumour cells (Giri et al, 1998; Li and
Karin, 1999; Manna et al, 2000). We therefore postulated that hGH
may act on apoptosis by downmodulation of ROI production. In
order to evaluate this hypothesis, we first assessed the effect of
hGH on the level of GSH, the most abundant intracellular thiol and
a powerful ROI scavenger. We found that hGH increased GSH
production in our tumour cells (Figure 4A). In parallel, we
observed that addition of GSH-OEt to unmodified U937 cells
exposed to TNF-a led to inhibition of NF-kB activation by IkBe
stabilisation (Figure 4C and D), thus mimicking the effect of hGH.
Moreover, GSH depletion with 50mM DEM, a potent thiol-
depleting agent, in hGH-producing cells exposed to TNF-a
restored the IkB degradation process (Figure 4D). Direct addition
of a GSH analog (GSH-OEt) able to enter cells due to its
hydrophobic ester groups also increased cell death in TNF-a-
treated cell cultures (Figure 4B), thus imitating the ability of hGH
to sensitise control U937 cells to TNF-a-induced apoptosis. These
last data are in apparent contradiction with several studies,
including our own, run in other cell types, showing that GSH
may protect cells from a death signal (De ´as et al, 1997). However,
in line with our findings, a report of experiments in U937
cells clearly revealed that antioxidant reagents may block NF-kB
activation and potentiate TNF-a-induced apoptosis (Shrivastava
and Aggarwal, 1999). Altogether, our findings clearly suggest
that hGH controls NF-kB activation and therefore apoptosis
via modification of the redox status of tumours exposed to
the anticancer drugs used in this study. Thus, depending on
the stimulus applied to the cells, hGH may either trigger (Jeay
et al, 2000), inhibit (as we have reported in human monocytes
exposed to lipopolysaccharides (Haeffner et al, 1997) or
decrease (as in the present study) translocation of NF-kB into
cell nuclei.
We finally decided to validate our findings in an in vivo model.
Owing to the high toxicity of TNF-a in vivo, we decided to treat
mice with the anticancer drug daunorubicin, one of the most
commonly used and broadly active chemotherapeutic agents.
Moreover, daunorubicin shares several properties with TNF-a, that
is, NF-kB stimulation (Das and White, 1997) and ROI production
(Gewirtz, 1999). This latter effect was correlated to deleterious
effects, such as severe cardiomyopathy observed in cancer patients
(Gewirtz, 1999). We then investigated the effect of recombinant
hGH injections in nude mice bearing xenografted tumours
concomitantly treated with the highest dose of daunorubicin
previously demonstrated to be devoid of animal toxicity. The
efficacy of hGH was confirmed by these experiments as, 6 days
after initiation of treatment, greater numbers of apoptotic cells
(Figure 5A) and cells displaying NF-kB inhibition (Figure 5B) were
observed in mice treated with both drug and rhGH than in the
other groups of mice. In parallel, the U937 tumour cell growth rate
was significantly decreased in mice treated with both daunorubicin
and rhGH, compared to U937 tumours in mice receiving
daunorubicin or rhGH or saline alone (Figure 5C). We speculate
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sthat more prolonged treatment would extend and improve the
efficacy of the therapeutic outcome.
Finally, our model may help to shed some light on one of the
various mechanisms controlling NF-kB activation. Following
binding to its receptors, hGH induces activation of the Janus
kinase 2 (Jak2) (Argetsinger et al, 1996), which in turn tyrosine-
phosphorylates signal transducers and activators of transcription
proteins (STAT) (Ram and Waxman, 1997). These phosphorylated
proteins migrate into the nucleus and, by binding to GH-
responsive elements, trigger gene transcription. These data must
be interpreted in the light of the recently proposed crosstalk
between NF-kB and STAT showing either an NF-kB-mediated
negative control of STAT phosphorylation (Geymayer and
Doppler, 2000), or alternatively, the inhibition of NF-kB mediated
by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore
conceivable that hGH may regulate NF-kB and consequently cell
apoptosis via a Jak-STAT-dependent mechanism; this hypothesis
is currently being investigated. This should be of interest in the
development of new therapeutic modalities designed to improve
anticancer chemotherapy.
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